Basic Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Feb 12, 2016; 5(1): 14-22
Published online Feb 12, 2016. doi: 10.5501/wjv.v5.i1.14
Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy
Mohamed A Daw, Amira Shabash, Abdallah El-Bouzedi, Aghnya A Dau, Moktar Habas, Libyan Study Group of Hepatitis and HIV
Mohamed A Daw, Acting Physician of Internal Medicine, Scientific Coordinator of Libyan National Surveillance Studies of Viral hepatitis and HIV, Tripoli 82668, Libya
Mohamed A Daw, Amira Shabash, Department of Medical Microbiology, Faculty of Medicine, Tripoli 82668, Libya
Abdallah El-Bouzedi, Department of Laboratory Medicine, Faculty of Biotechnology, Tripoli 82668, Libya
Author contributions: Daw MA designed the study, extracted the data, and drafted and finalized the manuscript; Shabash A and El-Bouzedi A collected the data and contributed to the drafting of the manuscript; Dau AA drafted, analyzed, and corrected the manuscript; Habas M collected the data and reviewed the clinical status of all patients; all authors read and approved the final manuscript.
Institutional review board statement: The study was reviewed by the board of Faculty of Medicine Tripoli Libya and found that the utilization and analysis of microbial epidemiological data did not require oversight by Libyan National Ethics committee. Hence no ethical approval was needed for this study.
Institutional animal care and use committee statement: We declare that no animals or human volunteers were used in the study.
Conflict-of-interest statement: All authors declare that there is no potential conflict of interests regarding this article.
Data sharing statement: All data will be made freely available via the corresponding author (mohamedadaw@gmail.com). There are no security or licensing matters related to the study.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed byexternal reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Mohamed A Daw, FTCDA, MD, MPS, PhD, Professor of Clinical Microbiology and Microbial Epidemiology, Department of Medical Microbiology, Faculty of Medicine, Alfrnaj Road, Tripoli 82668, Libya. mohamedadaw@gmail.com
Telephone: +218-91-2144972 Fax: +218-21-3366218
Received: May 11, 2015
Peer-review started: May 18, 2015
First decision: July 26, 2015
Revised: August 24, 2015
Accepted: September 16, 2015
Article in press: September 18, 2015
Published online: February 12, 2016

Abstract

AIM: To determine hepatitis C virus (HCV) seroprevalence among the Libyan population using blood donors and applying the autoregressive integrated moving average (ARIMA) model to predict future trends and formulate plans to minimize the burden of HCV infection.

METHODS: HCV positive cases were collected from 1008214 healthy blood donors over a 6-year period from 2008 to 2013. Data were used to construct the ARIMA model to forecast HCV seroprevalence among blood donors. The validity of the model was assessed using the mean absolute percentage error between the observed and fitted seroprevalence. The fitted ARIMA model was used to forecast the incidence of HCV beyond the observed period for the year 2014 and further to 2055.

RESULTS: The overall prevalence of HCV among blood donors was 1.8%, varying over the study period from 1.7% to 2.5%, though no significant variation was found within each calendar year. The ARIMA model showed a non-significant auto-correlation of the residuals, and the prevalence was steady within the last 3 years as expressed by the goodness-of-fit test. The forecast incidence showed an increase in HCV seropositivity in 2014, ranging from 500 to 700 per 10000 population, with an overall prevalence of 2.3%-2.7%. This may be extended to 2055 with minimal periodical variation within each 6-year period.

CONCLUSION: The applied model was found to be valuable in evaluating the seroprevalence of HCV among blood donors, and highlighted the growing burden of such infection on the Libyan health care system. The model may help in formulating national policies to prevent increases in HCV infection and plan future strategies that target the consequences of the infection.

Key Words: Autoregressive integrated moving average model, Libya, Hepatitis C virus, Blood donors

Core tip: Hepatitis C virus (HCV) infection has major consequences and an overwhelming impact particularly among developing countries, hence prediction of its prevalence is important for future planning to mitigate its impact. This is an innovative study highlighting the importance of using a modified mathematical model to forecast and predict the future prevalence and consequence of HCV infection using data collected from blood donors. The results will allow strategists in health care services to plan immediate and long-term policies.


Citation: Daw MA, Shabash A, El-Bouzedi A, Dau AA, Habas M, Libyan Study Group of Hepatitis and HIV. Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy. World J Virol 2016; 5(1): 14-22
INTRODUCTION

Hepatitis C virus (HCV) has been known to be one of the leading causes of chronic viral hepatitis with devastating consequences such as cirrhosis and hepatocellular carcinoma which are the major reasons for liver transplantation[1]. The geo-epidemiology of HCV infection varies greatly and is dynamic over time[2]. Indeed, 3% of the world’s population are chronically infected with HCV and over 3 million new infection occur each year[3]. Africa and Asia represent the largest reservoir of chronic HCV infection[4,5], though prevalence varies from one country to another and among regions within each country[2,3]. The prevalence of HCV infection are highest in Africa, ranging from 1% to 26%, and Egypt, Senegal, and Cameroon have the highest rates worldwide[6].

Hepatitis C is well documented in Libya and different studies have shown the prevalence of HCV infection and genotypes among Libyans[7-9]. Recently a comprehensive study in over 1% of the Libyan population has shown that the prevalence of HCV infection is 1.2%, varying from 0.6% to 2.2% according to the region within the country[10]. The prevalence indicated an alarming increase in HCV among the younger generation, particularly within new emerging risk groups in Libyan society such as intravenous drug users (IVDUs)[10,11]. As age increases and disease progresses among infected individuals, there will be an increase in expected complications. This will place an increasing burden on the Libyan health care system which is still developing. Hence, studies should be directed to formulate policies to combat the effects of infection.

Early identification of epidemics of infectious diseases and prediction of their outcomes are an important step toward implementing effective intervention measurements and reducing mortality and morbidity[12]. Such goals are a challenge in health care surveillance studies. Mathematical dynamic modeling has contributed greatly in exploring such challenges. Surveillance data however, are usually necessary for these modeling purposes[13].

Different statistical models including linear regression and correlation coefficients have been used for prediction of viral hepatitis. Autoregressive integrated moving average (ARIMA) or Box-Jenkins has potential application in studies of disease dynamics[14]. Helfinstein was the first to show that the ARIMA model can be used successfully for forecasting and predicting the different relationships between viral infections and associated diseases[15]. Different studies applied such modeling to detect spikes, steps, and trends for hepatitis E, hepatitis B and hepatitis C infection[16,17]. A considerable effort has been undertaken to forecast the epidemiology of hepatitis C, and different models were used to estimate the burden and complications of the infection[18]. Recently, Corson et al[19] used a mathematical model to project the future of HCV among IVDUs and its impact on the future development of HCV-related morbidity and mortality.

Blood donors are generally considered to be a healthier cohort of any community and viral hepatitis seropositivity among them may mirror the seroprevalence in the general population[20]. In Libya, a study conducted between 1991 and 2001 indicated that the prevalence of HCV infection ranged from 1.2% to 1.6% among blood donors, similar to the prevalence among the general population reported in 2014 of 1.2%, though it was much higher (20.5%) among hospital personnel[7,10]. Therefore, modeling and forecasting using HCV data from blood donors may provide an opportunity for planning and intervention to control HCV infection. In this study, we aimed to forecast the prevalence of HCV trends among blood donors by analyzing HCV dynamics and highlighting the need for further intervention strategies.

MATERIALS AND METHODS
Ethical consideration

The study was reviewed by the Board of the Faculty of Medicine, Tripoli, Libya, who declared that the utilization and analysis of microbial epidemiological data did not require oversight by the Libyan National Ethics Committee. Hence, no ethical approval was needed for this study.

Study population

A total of 1008214 healthy individuals, aged 18 to 50 years, were recruited from three different main blood banks in Tripoli over 6 years from 2008-2013 (Table 1). These included Tripoli Central Hospital, Karda Teaching Hospital, and Tripoli Reference Laboratory. Each person was subjected to screening for known risk factors associated with blood donation according to the national and international standards applicable in all three hospitals. Those who failed to meet the criteria for blood donation were excluded from the study, such as those who had previous blood transfusion, jaundice, a history of illicit drug-taking, and other potential risk factors.

Table 1 Number of blood donors included in the study, Tripoli, Libya, 2008-2013.
Study periodNo. of volunteersNo. HCV seropositive
200835859937
2009653301713
20102541773958
20111738733060
20122601394480
20132188363749
Total100821417897
Laboratory diagnosis

The laboratory analysis was carried out using ELISA (Vitros EciQ, Orthodiagnostic-Switzerland), and samples were considered to be confirmed positive according to the manufacturer’s instructions. HCV infection was defined as the presence of anti-HCV antibodies in the serum as detected by ELISA.

Modeling

The ARIMA model was developed to forecast the incidence of HCV infection among blood donors in Libya. This was applied using data for 72 mo between January 2008 and December 2013 to then forecast the incidence of HCV infection from January to December 2014 and predict the prevalence of HCV infection from 2008 to 2055 under nonexclusive expectation. The model was constructed using the Box-Jenkins method. The identification and selection steps for ARIMA were carried via autocorrelation and partial autocorrelation functions. The model parameters were determined by the maximum likelihood method. Goodness-of-fit among ARIMA models was compared using diagnostic checks such as residual analysis and other relevant information. The accuracy of the model was finally subjected to critical estimation and rigorous checking to fulfill the required criteria for the model. The details of the ARIMA model were recently described by Yu et al[21] in 2013 and used to analyze the epidemiology of HIV infection among the Korean population.

Statistical analysis

Data were analyzed using Microsoft Excel, Minitab version 15 (State College, PA, United States), and SPSS version 16 (SPSS Inc., Chicago, IL, United States). A P-value < 0.05 indicated a significant difference between HCV and HBV prevalence. The Excel 2007 forecast function was used to predict the number of infected people. The following equation was used to calculate the expected number of infected persons each year, 1-Y = 613.2X + 836.5, where Y = number of expected infected persons with HCV, and X = the serial number for the year calculated from 2008; for example for 2009 and 2010 the serial numbers were 2 and 3, respectively.

RESULTS

A total of 1008214 volunteer blood donors were screened for HCV over a 6-year period from 2008 till 2013. Of these, 17897 were found to be positive for anti-HCV antibodies, with an overall prevalence of 1.8%. There was no apparent monthly difference in HCV infection among individuals screened during the same year. Based on year-to-year analysis, a substantial variation in the seroprevalence of HCV was observed as shown in Table 2. The highest prevalence of HCV infection was reported in 2008 and 2009 as (2.6%) though it was 1.5% in 2010 and 1.7% in 2011-2013. In 2008, 35869 individuals were reviewed, of whom 937 (2.6%) were positive for anti-HCV antibodies. During 2009 the number of screened people doubled, and 1713 (2.6%) were positive for anti-HCV antibodies. In 2010, the number screened was 254177, a 7-fold increase compared with 2008, and 3958 (1.5%) were positive for HCV antibodies. In 2011, 3060 (1.7%) were HCV-positive. Although 260139 people were screened during 2012, the largest number over the 5-year period, the prevalence was the same (1.7%) as to that in 2011 and 2013, when a combined total of 218836 persons were screened (Table 1).

Table 2 Seroprevalence of hepatitis C virus among blood donors, Tripoli, Libya, 2008-2013.
YrPrevalence (%)OR95%CI
MinimumMaximum
LowerUpper
20082.61.42.32.82.03.2
20092.61.41.73.41.14.1
20101.50.81.31.60.92.1
20111.70.71.32.00.82.8
20121.71.10.82.60.62.9
20131.71.10.92.50.72.7
Total1.81.11.42.51.03.0

ARIMA modeling was applied to the data for identification, estimation, and then forecasting of HCV infection. The first stage was construction of an estimation model followed by forecasting and model evaluation. The data collected from 2008-2013 was used to construct the ARIMA model as depicted by Box et al[14]. Figure 1 shows the sample autocorrelation and partial autocorrelation functions [autocorrelation function (ACF) and partial ACF (PACF)] for the case structure which allowed identification of an appropriate ARIMA form to model the stationary series. A small variation was noted but it was not statistically different from zero which confirms the adequacy of the ARIMA model. The model forecast a steady increase for the following 6 years.

Figure 1
Figure 1 Correlogram and partial correlogram for a case structure control used for autoregressive integrated moving average model. A: ACF; B: Partial ACF. ACF: Autocorrelation function.

The sample ACF and PACF in Figure 2 showed a good fit which allowed us to determine the appropriate ARIMA model for HCV seroprevalence among blood donors. The adequacy of the model was evident as the residuals of autocorrelation had little variation with no significant difference (P > 0.05).

Figure 2
Figure 2 Residual plots for the final autoregressive integrated moving average (2, 1, 7) model of hepatitis C virus seroprevalence among volunteer blood donors in Libya, 2008-2013. A: ACF; B: Partial ACF. Lines indicate 95%CI. ACF: Autocorrelation function.

The plot of observed vs fitted values indicated that the model provided an excellent fit of the data as shown in Figure 3. The ARIMA model was used to forecast HCV prevalence for 72 mo over the 6-year period from January 2008 to December 2013 (Figure 3). Detailed analysis of observed vs forecast values of HCV prevalence over the study period showed a steady increase, with a maximum value at 1.8% to 2.01%, and an increasing tendency beyond the observed period in the short-term forecast (January-December 2014), reaching a maximum of 700 per 10000 population (2.3% to 2.7%). This was then used as a basis for estimating the prevalence of HCV infection among the Libyan population up to 2055, based on 6-year periods (Figure 4). According to our model, the prevalence of HCV infection will decrease and thus all sequelae of the infection will continue to decrease steadily in the future.

Figure 3
Figure 3 Number of observed and forecast hepatitis C virus seropositive volunteers among blood donors in Libya, 2008-2013. Date: Period of observation (months: 2008-2013); Number: Estimated number of HCV seropositive/month. UCL: Upper confidence limit; LCL: Lower confidence limit; HCV: Hepatitis C virus.
Figure 4
Figure 4 Modeled prevalence (not exclusive1) of hepatitis C virus infection by 6-year period, Libya, 2008-2055. 1Estimates assume stable risk populations and HCV infection risks and do not adjust for treatment. HCV: Hepatitis C virus.
DISCUSSION

HCV infection has been known to be an important cause of chronic liver diseases though accurate representative epidemiological data are difficult to obtain, particularly in developing countries, as this infection has been considered to be endemic[2]. Statistical analysis of surveillance data on the prevalence of various infections was shown to be helpful in establishing a hypotheses to highlight and anticipate the dynamics of HCV infection and subsequently implement appropriate preventive measures and allocation of required resources[22]. The ARIMA model is one of the most widely used forecasting techniques due to its structured modeling base and acceptable forecasting performance[23].

In this study, we developed a calibrated ARIMA model for HCV infection with the aim of taking full advantage of available epidemiological information from registered blood donors in Libyan blood banks. The overall prevalence of HCV among the blood donors was found to be 1.8%, ranging from 2.5% in 2008 to 1.7% in 2013. This is consistent with a recent comprehensive study published by our group who reported that the prevalence of HCV among the Libyan population varied from 0.6% to 2.2%[10]. Comparing such results with regional published data, the prevalence of HCV infection was found to be similar to that in neighboring countries, with 1.6% in Tunis and 1.8% in Algeria, though it was higher in Egypt (22%)[24,25]. However, this was higher than the prevalence among developed countries such as the United States and Germany (< 1.5%)[26,27]. Hence, further studies are needed to elucidate the different factors associated with the higher prevalence of HCV among Libyan blood donors.

In our study, the applied model showed accuracy for the prevalence and dynamics of HCV infection among blood donors over a 6-year period and the forecast after that. This is in agreement with other studies who also declared that this model provides a better forecast than traditional methods for case notification of an infectious disease[28]. Although the prevalence of HCV was steady over the last 3 years (1.7% for 2011-2013), we predicted an increase for the year after. This was consistent with other studies from China and Latin America which showed that the prevalence of HCV was steady or increasing and that the number of infected individuals will increase[29,30]. This suggested that other risk factors are set to play a major role in continued new infection. Further studies are needed to clarify such an assumption.

Despite the increase in rates of HCV seropositivity in this study, we did not predict the burden of HCV infection over the next decades, nor did we calculated the estimated number of individual morbidities associated with HCV infection. However, different studies have shown that the prevalence of HCV-related cirrhosis is expected to increase by 24% within a decade, though decompensated cirrhosis cases and hepatocellular carcinoma will increase by 50% within the same period[31-33]. Hence, further studies are needed to elucidate such consequent complications of HCV infection among Libyan populations.

Modeling studies have projected a dismal future for HCV infection and related disease burden. In general, these models make forecasts based on current conditions of low rates of screening and treatment, and thus do not include a widespread program of identifying and treating the large proportion of undiagnosed HCV-infected individuals[34]. According to the results of our model, the incidence of the more serious outcomes of HCV infection will continue to rise, at least until 2055, unless modified. In our projections of HCV infection to 2055, we did not take into account the effective HCV prevention programs and the possible impact of the use of antiviral medications. Both these developments could have a considerable impact on our future projections, and thus the prevalence of HCV infection projected to 2055 may be less than that estimated by our model. Furthermore, socioeconomic conditions in the country should be taken in consideration, particularly among developing countries; Libya is experiencing a major challenge regarding its geographical, political and social-ethnic identity[35,36]. Thus, future planning regarding infectious disease should be prioritized[37,38].

Monitoring HCV seropositivity among blood donors could be used to evaluate the effectiveness of the national efforts and guidelines to provide safe blood donation and good blood bank services[39]. In many countries, HCV transmission rates decreased markedly with the introduction of blood screening[40]. Despite such a decline, mathematical models still predict a continuing rise in the prevalence of HCV infection within blood banks[41]. This was evident in our study where the increase in HCV seroprevalence may be attributed to the lack of quality assurance within the blood donation system. In Arab countries, blood transfusion is still a problem due to lack of an organized infrastructure and altruistic volunteers. The main sources of blood donation are usually relatives and friends who attend because of social pressure and in an emergency where questions regarding risk behaviors are rarely asked[2].

Many difficulties surround the determination of HCV prevalence using blood donors, since high risk groups including IVDUs are often excluded from blood donation, leading to underestimation of the true prevalence of HCV infection[42]. Nevertheless, our data do not necessarily represent the true HCV prevalence among the general population and thus are in need of further updating. The applicability and effectiveness of this monitoring system in its practical application as conducted here is able to detect the epidemic situation of HCV infection in Libya. However, such an infection is dynamic and evolves over time. Therefore, the model should be periodically reassessed and updated to maintain long-term sustainability and precision. This study highlights the need for preventive initiatives and strategies to be adapted by health care policy-makers to reduce HCV infection.

In conclusion, there is an important need for monitoring and predicting the prevalence of HCV infection to reduce the substantial consequences particularly in developing countries. The model applied was verified and could be used to monitor and predict the epidemiology of HCV infection. A better understanding of the epidemiology of HCV infection will allow health authorities to revise and plan new strategies within the health care system.

ACKNOWLEDGMENTS

The authors would like to acknowledge the help and assistance of blood banks in Tripoli, and the Libyan Reference Laboratory. Further thanks should go to Dr Reiad M Gaja, Department of Statistics, Faculty of Science-Tripoli University for his comments on the model applied.

COMMENTS
Background

Viral hepatitis, particularly hepatitis C virus (HCV) is known to be a serious problem particularly among developing countries. Hence, using a simple and reliable method for predicting the future course and consequences of this infection are a priority for researchers and health care planners. Reliable data regarding the prevalence of HCV infection among blood donors are available in all blood banks and this could be used to achieve such objectives.

Research frontiers

Studies on the prevalence of HCV infection utilizing blood bank data could be used as a basis for future planning. However, such studies are rare and few researchers have focused on using such data as a model for future planning.

Innovations and breakthroughs

This is a novel study which applied a mathematical model utilizing basic data from blood banks regarding the pathogen HCV. This is a rare study which modeled data to predict the prevalence of HCV infection among the general population over the next 50 years (2008-2055).

Applications

The practical approach of this study allows strategists and health care professionals to plan appropriate intervention and prevention methods not only to minimize the spread of HCV infection but also to reduce the associated consequences and complications, such as hepatocellular carcinoma and cirrhosis, and may be used further for other infections such as hepatitis B virus and human immunodeficiency virus.

Terminology

The ARIMA model is an autoregressive integrated moving average or Box-jenkins mathematical model which has a potential application in studying disease dynamics. The model can be used successfully for forecasting and predicting the relationships among viral infections and associated diseases.

Peer-review

This is a well conducted epidemiologic study carried out in a developing country.

Footnotes

P- Reviewer: Borzio M, Smith MA S- Editor: Gong XM L- Editor: Cant MR E- Editor: Li D

References
1.  Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis. 2014;16:1-16.  [PubMed]  [DOI]
2.  Daw MA, Dau AA. Hepatitis C virus in Arab world: a state of concern. Sci World J. 2012;2012:719494.  [PubMed]  [DOI]
3.  Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-1342.  [PubMed]  [DOI]
4.  Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J. 2013;14:44.  [PubMed]  [DOI]
5.  Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894.  [PubMed]  [DOI]
6.  Jobarteh M, Malfroy M, Peterson I, Jeng A, Sarge-Njie R, Alabi A, Peterson K, Cotten M, Hall A, Rowland-Jones S. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J. 2010;7:230.  [PubMed]  [DOI]
7.  Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J. 2002;23:1356-1360.  [PubMed]  [DOI]
8.  Elasifer HA, Agnnyia YM, Al-Alagi BA, Daw MA. Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients. Virol J. 2010;7:317.  [PubMed]  [DOI]
9.  Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012;12:265.  [PubMed]  [DOI]
10.  Daw MA, El-Bouzedi A. Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey. BMC Infect Dis. 2014;14:17.  [PubMed]  [DOI]
11.  Daw MA, Dau AA, Agnan MM. Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. ScientificWorldJournal. 2012;2012:580216.  [PubMed]  [DOI]
12.  Rong L, Guedj J, Dahari H, Perelson AS. Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Antivir Ther. 2014;19:469-477.  [PubMed]  [DOI]
13.  Chatterjee A, Guedj J, Perelson AS. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? Antivir Ther. 2012;17:1171-1182.  [PubMed]  [DOI]
14.  Box GEP, Jenkins GM.  Time series analysis, control, and forecasting. San Francisco, CA: Holden Day; 1976;10.  [PubMed]  [DOI]
15.  Helfenstein U. Box-Jenkins modelling of some viral infectious diseases. Stat Med. 1986;5:37-47.  [PubMed]  [DOI]
16.  Ren H, Li J, Yuan ZA, Hu JY, Yu Y, Lu YH. The development of a combined mathematical model to forecast the incidence of hepatitis E in Shanghai, China. BMC Infect Dis. 2013;13:421.  [PubMed]  [DOI]
17.  Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis. 2006;6:93.  [PubMed]  [DOI]
18.  Akhtar S, Carpenter TE. Stochastic modelling of intra-household transmission of hepatitis C virus: evidence for substantial non-sexual infection. J Infect. 2013;66:179-183.  [PubMed]  [DOI]
19.  Corson S, Greenhalgh D, Taylor A, Palmateer N, Goldberg D, Hutchinson S. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing. Drug Alcohol Depend. 2013;133:172-179.  [PubMed]  [DOI]
20.  Khodabandehloo M, Roshani D, Sayehmiri K. Prevalence and trend of hepatitis C virus infection among blood donors in Iran: A systematic review and meta-analysis. J Res Med Sci. 2013;18:674-682.  [PubMed]  [DOI]
21.  Yu HK, Kim NY, Kim SS, Chu C, Kee MK. Forecasting the number of human immunodeficiency virus infections in the korean population using the autoregressive integrated moving average model. Osong Public Health Res Perspect. 2013;4:358-362.  [PubMed]  [DOI]
22.  Firmino PR, de Mattos Neto PS, Ferreira TA. Correcting and combining time series forecasters. Neural Netw. 2014;50:1-11.  [PubMed]  [DOI]
23.  Zhang X, Zhang T, Young AA, Li X. Applications and comparisons of four time series models in epidemiological surveillance data. PLoS One. 2014;9:e88075.  [PubMed]  [DOI]
24.  Ezzikouri S, Pineau P, Benjelloun S. Hepatitis B virus in the Maghreb region: from epidemiology to prospective research. Liver Int. 2013;33:811-819.  [PubMed]  [DOI]
25.  Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat. 2013;20:294-296.  [PubMed]  [DOI]
26.  Sheikh MY, Atla PR, Ameer A, Sadiq H, Sadler PC. Seroprevalence of Hepatitis B and C Infections among Healthy Volunteer Blood Donors in the Central California Valley. Gut Liver. 2013;7:66-73.  [PubMed]  [DOI]
27.  Offergeld R, Ritter S, Hamouda O. [HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008-2010]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55:907-913.  [PubMed]  [DOI]
28.  Liu Q, Liu X, Jiang B, Yang W. Forecasting incidence of hemorrhagic fever with renal syndrome in China using ARIMA model. BMC Infect Dis. 2011;11:218.  [PubMed]  [DOI]
29.  Ji ZH, Li CY, Lv YG, Cao W, Chen YZ, Chen XP, Tian M, Li JH, An QX, Shao ZJ. The prevalence and trends of transfusion-transmissible infectious pathogens among first-time, voluntary blood donors in Xi’an, China between 1999 and 2009. Int J Infect Dis. 2013;17:e259-e262.  [PubMed]  [DOI]
30.  Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, Quiroz JF, Rodriguez-Perez F, Rosado B. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int. 2011;31 Suppl 2:18-29.  [PubMed]  [DOI]
31.  Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, Hansen T, Pitton MB, Düber C, Otto G. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol. 2014;48:279-289.  [PubMed]  [DOI]
32.  Pinchoff J, Drobnik A, Bornschlegel K, Braunstein S, Chan C, Varma JK, Fuld J. Deaths among people with hepatitis C in New York City, 2000-2011. Clin Infect Dis. 2014;58:1047-1054.  [PubMed]  [DOI]
33.  Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int. 2011;31 Suppl 2:4-17.  [PubMed]  [DOI]
34.  Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Towards a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;Jul 14; Epub ahead of print.  [PubMed]  [DOI]
35.  Daw MA, El-Bouzedi A, Dau AA. Libyan armed conflict 2011: Mortality, injury and population displacement. Afr J Emerg Med. 2015;14:101-107.  [PubMed]  [DOI]
36.  Daw MA, El-Bouzedi A, Dau AA. The assessment of efficiency and coordination within Libyan Healthcare System during the Armed Conflict-2011. Clinical Epidemiology & Global Health. 2015;In press.  [PubMed]  [DOI]
37.  Daw MA, El-Bouzedi A, Dau AA. Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. BMC Res Notes. 2015;8:367.  [PubMed]  [DOI]
38.  Daw MA, El-Bouzedi A. Viral haemorrhagic fever in North Africa; an evolving emergency. J Clin Exp Pathol. 2015;5:215.  [PubMed]  [DOI]
39.  Watkins NA, Dobra S, Bennett P, Cairns J, Turner ML. The management of blood safety in the presence of uncertain risk: a United kingdom perspective. Transfus Med Rev. 2012;26:238-251.  [PubMed]  [DOI]
40.  Kim MJ, Park Q, Min HK, Kim HO. Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010. BMC Infect Dis. 2012;12:160.  [PubMed]  [DOI]
41.  Lucky TT, Seed CR, Keller A, Lee J, McDonald A, Ismay S, Wand H, Wilson DP. Trends in transfusion-transmissible infections among Australian blood donors from 2005 to 2010. Transfusion. 2013;53:2751-2762.  [PubMed]  [DOI]
42.  Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50:1495-1504.  [PubMed]  [DOI]